Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.

ABSTRACT:

Objectives

The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung cancer.

Background

ICIs activate the host immune system to target cancer cells. Though uncommon, cardiovascular immune-related adverse events can be life-threatening.

Methods

A retrospective single-institution cohort study of 252 patients with pathologically confirmed lung cancer who received ICI or non-ICI therapy was analyzed. The primary endpoint was MACE, defined as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.

Results

During a median follow-up of 6

SUBMITTER: Chitturi KR 

PROVIDER: S-EPMC8352266 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature